Clinical Trials Logo

Residual Tumor clinical trials

View clinical trials related to Residual Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05956977 Recruiting - Residual Tumor Clinical Trials

Evaluation of 3D Ultrasound in Brain Tumor Surgery

Neuro3DUS
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Evaluation of impact of use of 3D ultrasound in brain tumor surgery on extend of resection. Benefit for surgery, neurological outcome, accuracy and image quality are secondary outcome parameters. Control group is a retrospective matched pair cohort.

NCT ID: NCT02670109 Recruiting - Clinical trials for Triple-Negative Invasive Breast Carcinoma

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

Start date: February 1, 2018
Phase: Phase 2
Study type: Interventional

Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is approximately 180,000 cases per year. TNBC are known to be more aggressive with poor prognosis specially when no pathologic complete response (pCR) is achieved after neoadjuvant chemotherapy, with a higher risk of recurrence and a poor survival once that recurrence occurs. On the other hand, there is not a specific adjuvant or neoadjuvant treatment for these patients. Since autologous hematopoietic stem cell transplantation (HSCT) allows the usage of higher doses of chemotherapy, which results in higher cellular destruction with a decrease of hematological toxicity, it is proposed that this procedure is able to improve prognosis in TNBC patients with no pathologic complete response after neoadjuvant chemotherapy.